Have you ever wondered why SSRIs take time to show effects? A new study has delved into why antidepressants like SSRIs take weeks to start working and how this may impact mental health care.

---

SSRIs, or Selective Serotonin Reuptake Inhibitors, belong to a category of antidepressant drugs designed to elevate serotonin levels in the brain. Notable examples of SSRIs include fluoxetine (Prozac), sertraline (Zoloft), and escitalopram (Lexapro).

These medications generally have few unpleasant side effects and can be highly effective in treating various mood disorders, including depression and certain anxiety disorders. However, one significant drawback of SSRIs is the delayed onset of their therapeutic effects — SSRIs often take several weeks to show noticeable improvements in mood.

This extended period before “kicking in” poses challenges for patients and healthcare providers. Yet, the reason behind this lag in action is not well understood.

Jeanette Norden, Professor of Cell and Developmental Biology, Emerita, Vanderbilt University School of Medicine, explores how the brain learns and remembers. This video focuses on a discussion of how the brain is organized in general.

These lectures will provide the foundation.
information necessary to the understanding.
of the lectures which will follow. A special.
emphasis will be given to systems in the brain.
that underlie learning and memory, attention.
and awareness. These introductory lectures.
will be followed by a lecture on how different.
areas of the brain encode different, specific.
types of information—from the phone number.
we need only remember for a few minutes or.
less to the childhood memories we retain for.
a lifetime. We will also address the \.

With depression affecting around 1 in 10 of us at some point during our lives, the need for new and improved treatments is a top priority for researchers – and it appears that spinal cord stimulation could be one route for experts to investigate.

A team led by researchers at the University of Cincinnati College of Medicine devised a pilot clinical trial in which a little black box was placed on the spinal cord of 20 volunteers with depression, with one electrode on the back and one on the right shoulder.

The box then delivered a specially customized, low-level electric buzz to half of the volunteers, for three sessions per week over eight weeks. This was shown to have a greater effect on depressive symptoms than the different, ‘placebo’ charge administered to the other half of the volunteers.

Discovery could be useful in developing new therapies for multiple sclerosis, neurodegenerative conditions, and brain cancer.

New research from Oregon Health & Science University for the first time reveals the function of a little-understood junction between cells in the brain that could have important treatment implications for conditions ranging from multiple sclerosis to Alzheimer’s disease, to a type of brain cancer known as glioma.

The study will be published today (January 12) in the journal Nature Neuroscience.